India, June 15 -- Johnson & Johnson (JNJ) announced positive results from its Phase 3 MonumenTAL-3 trial evaluating Talvey in combination with Darzalex Faspro, with or without pomalidomide, for the treatment of patients with relapsed/refractory Multiple Myeloma.
Talvey, as monotherapy, was granted accelerated approval by the FDA in 2023 for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
In the phase 3 MonumenTAL-3 trial, TALVEY plus DARZALEX FASPRO with or without pomalidomide reduced the risk of disease progression or death by up to 72% and lowered the risk of death ...